Instead of preventing cancer, therapeutic tumor vaccines are designed to treat existing cancers, mainly by stimulating a cytotoxic T-lymphocyte (CTL) immune response against particular antigens expressed on the surface of tumor cells in the context of major histocompatibility complexes (MHC) [11,13]. This evidence concerns the gene HLA-C and cancer.